Linagliptin safety profile: A systematic review.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 29853297.
- Also identified by DOI 10.1016/j.pcd.2018.04.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To describe the safety profile of linagliptin. Systematic review using PubMed/MEDLINE, BVS and Web of Science. The search strategy "Linagliptin" AND "safety" was used. The inclusion criteria were clinical trials with a control group composed of conventional DM2 pharmacotherapy. We identified 16 studies, and the most frequent adverse events (AEs) were nasopharyngitis with linagliptin at 5 and 10mg in monotherapy (31.6% and 29.6%, respectively) and gastrointestinal events (>10.0%) with linagliptin in combination. Of the AEs, 14.9 (±3.1)% were associated with the use of linagliptin in monotherapy, and 17.6 (±6.0)% in combination. The linagliptin AEs have a varied occurrence and frequency, ranging from mild to moderate intensity.
Medical subject headings
- Blood Glucose
- Diabetes Mellitus, Type 2
- Dipeptidyl-Peptidase IV Inhibitors
- Linagliptin